MedTrace Logo

Inappropriate Prescription in Elderly and Polypharmacy Patients in Primary Care (PHARM-PC) Trial

NCT02224833 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 549

Last updated 2016-07-27

No results posted yet for this study

Summary

PHARM-PC study is based on identify potentially inappropriate prescriptions (PIP) and delivery therapeutic appropriateness recommendations from the pharmacist to the physician and about drugs prescribed for elderly and polypharmacy patients in primary care. Assessment of the impact of pharmacist intervention on the appropriateness of prescribing and both health outcomes and economic outcomes will be done.

Conditions

  • Elderly (People Aged 65 or More)
  • Polypharmacy (People Under Treatment With 5 or More Drugs)

Interventions

BEHAVIORAL

Pharmacist intervention

Systematic review of treatments: Identification of reasons for PPI. * Determination of recommended pharmacotherapeutic alternatives. * Issue recommendations for therapeutic appropriateness to the doctor (via registration on the EHR and verbal communication if deemed appropriate); that will be of 4 types: Add medicine, discontinue medicine, adjust dosage, replace medicine. After the medical visit (the next day) New treatment review for: Checking acceptance or rejection of the recommendations issued, review potential new prescriptions made without pharmacist recommending, and whether these new drugs lead to PIP.

Sponsors & Collaborators

  • Hospital Comarcal de Inca

    lead OTHER

Principal Investigators

  • Jesús Martínez, Pharm D · Hospital Comarcal de Inca

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-12-31
Completion
2016-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02224833 on ClinicalTrials.gov